FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040406100> ?p ?o ?g. }

• W2040406100 endingPage "20" @default.
• W2040406100 startingPage "13" @default.
• W2040406100 abstract "Preclinical data have demonstrated that the combination of antihuman epidermal growth factor receptor-2 (anti-HER2) and antivascular endothelial growth factor (anti-VEGF)--targeted agents has antitumor activity; these data indicate certain patients with HER2-overexpressing breast cancer may derive clinical benefit from this combination. The purpose of this single-arm phase II study was to determine the efficacy and safety of the dual-targeting combination of lapatinib and bevacizumab. Women with HER2-overexpressing advanced breast cancer received 1,500 mg oral lapatinib daily plus 10 mg/kg IV bevacizumab every 2 weeks. The primary endpoint was progression-free survival (PFS) at week 12; secondary endpoints included overall tumor response rate (ORR), clinical benefit rate (CBR), duration of response, time-to-response, PFS, and safety. Circulating tumor cells (CTC) and circulating endothelial cells (CEC) were measured at baseline and during study treatment as potential response markers. Fifty-two patients with stage IV disease were enrolled. The 12-week investigator-assessed PFS rate was 69.2% (95% confidence interval [CI]: 54.9, 81.3). Median PFS was 24.7 weeks (95% CI: 20.4, 35.1), and the CBR was 30.8% (95% CI: 18.7, 45.1). Of 45 patients with measurable disease, 6 were determined to have a partial response per Response Evaluation Criteria in Solid Tumors (ORR: 13.3%; 95% CI: 5.1, 26.8). The most common adverse events (AEs) included diarrhea, rash, and fatigue; most of these were either grade 1 or 2. Clinical responses were correlated with decreases in CTC and CEC. Lapatinib plus bevacizumab was active in patients with HER2-overexpressing breast cancer. The AE profile of the combination was consistent with the known profiles for these agents." @default.
• W2040406100 created "2016-06-24" @default.
• W2040406100 creator A5009941371 @default.
• W2040406100 creator A5015935463 @default.
• W2040406100 creator A5022031163 @default.
• W2040406100 creator A5026406867 @default.
• W2040406100 creator A5047713528 @default.
• W2040406100 creator A5053577410 @default.
• W2040406100 creator A5062088699 @default.
• W2040406100 creator A5065015623 @default.
• W2040406100 creator A5069795948 @default.
• W2040406100 creator A5078449638 @default.
• W2040406100 creator A5089854711 @default.
• W2040406100 creator A5090188675 @default.
• W2040406100 date "2011-12-24" @default.
• W2040406100 modified "2023-10-16" @default.
• W2040406100 title "A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer" @default.
• W2040406100 cites W1968539943 @default.
• W2040406100 cites W1989918016 @default.
• W2040406100 cites W1999882636 @default.
• W2040406100 cites W2012784647 @default.
• W2040406100 cites W2032037224 @default.
• W2040406100 cites W2062003573 @default.
• W2040406100 cites W2068014745 @default.
• W2040406100 cites W2095156669 @default.
• W2040406100 cites W2101824720 @default.
• W2040406100 cites W2111976640 @default.
• W2040406100 cites W2115330997 @default.
• W2040406100 cites W2115759102 @default.
• W2040406100 cites W2117342140 @default.
• W2040406100 cites W2124272716 @default.
• W2040406100 cites W2139248078 @default.
• W2040406100 cites W2141393790 @default.
• W2040406100 cites W2141696951 @default.
• W2040406100 cites W2143738177 @default.
• W2040406100 cites W2146384083 @default.
• W2040406100 cites W2148479421 @default.
• W2040406100 cites W2149908785 @default.
• W2040406100 cites W2152142449 @default.
• W2040406100 cites W2248175895 @default.
• W2040406100 cites W2523320031 @default.
• W2040406100 cites W2575566375 @default.
• W2040406100 cites W4242373679 @default.
• W2040406100 cites W4247664461 @default.
• W2040406100 doi "https://doi.org/10.1007/s10549-011-1918-z" @default.
• W2040406100 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3397213" @default.
• W2040406100 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22198412" @default.
• W2040406100 hasPublicationYear "2011" @default.
• W2040406100 type Work @default.
• W2040406100 sameAs 2040406100 @default.
• W2040406100 citedByCount "42" @default.
• W2040406100 countsByYear W20404061002012 @default.
• W2040406100 countsByYear W20404061002013 @default.
• W2040406100 countsByYear W20404061002014 @default.
• W2040406100 countsByYear W20404061002015 @default.
• W2040406100 countsByYear W20404061002016 @default.
• W2040406100 countsByYear W20404061002017 @default.
• W2040406100 countsByYear W20404061002019 @default.
• W2040406100 countsByYear W20404061002020 @default.
• W2040406100 countsByYear W20404061002022 @default.
• W2040406100 countsByYear W20404061002023 @default.
• W2040406100 crossrefType "journal-article" @default.
• W2040406100 hasAuthorship W2040406100A5009941371 @default.
• W2040406100 hasAuthorship W2040406100A5015935463 @default.
• W2040406100 hasAuthorship W2040406100A5022031163 @default.
• W2040406100 hasAuthorship W2040406100A5026406867 @default.
• W2040406100 hasAuthorship W2040406100A5047713528 @default.
• W2040406100 hasAuthorship W2040406100A5053577410 @default.
• W2040406100 hasAuthorship W2040406100A5062088699 @default.
• W2040406100 hasAuthorship W2040406100A5065015623 @default.
• W2040406100 hasAuthorship W2040406100A5069795948 @default.
• W2040406100 hasAuthorship W2040406100A5078449638 @default.
• W2040406100 hasAuthorship W2040406100A5089854711 @default.
• W2040406100 hasAuthorship W2040406100A5090188675 @default.
• W2040406100 hasBestOaLocation W20404061001 @default.
• W2040406100 hasConcept C121608353 @default.
• W2040406100 hasConcept C126322002 @default.
• W2040406100 hasConcept C143998085 @default.
• W2040406100 hasConcept C197934379 @default.
• W2040406100 hasConcept C203092338 @default.
• W2040406100 hasConcept C2775930923 @default.
• W2040406100 hasConcept C2776694085 @default.
• W2040406100 hasConcept C2777329042 @default.
• W2040406100 hasConcept C2777802072 @default.
• W2040406100 hasConcept C2778570526 @default.
• W2040406100 hasConcept C2779786085 @default.
• W2040406100 hasConcept C2779984678 @default.
• W2040406100 hasConcept C31760486 @default.
• W2040406100 hasConcept C530470458 @default.
• W2040406100 hasConcept C535046627 @default.
• W2040406100 hasConcept C71924100 @default.
• W2040406100 hasConceptScore W2040406100C121608353 @default.
• W2040406100 hasConceptScore W2040406100C126322002 @default.
• W2040406100 hasConceptScore W2040406100C143998085 @default.
• W2040406100 hasConceptScore W2040406100C197934379 @default.
• W2040406100 hasConceptScore W2040406100C203092338 @default.
• W2040406100 hasConceptScore W2040406100C2775930923 @default.
• W2040406100 hasConceptScore W2040406100C2776694085 @default.

• next